中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (05): 365-368.doi: 10.3969/j.issn.1671-4091.2022.05.014

• 综述 • 上一篇    下一篇

抗Xa因子活性检测在血液透析患者低分子肝素抗凝中的应用进展

王振兴 徐冷楠 付沛颉 党心 毛永辉   

  1. 北京医院国家老年医学中心北京大学医学部第五临床医学院肾内科
  • 收稿日期:2021-11-08 修回日期:2021-12-05 出版日期:2022-05-12 发布日期:2022-05-12
  • 通讯作者: 毛永辉 E-mail:maoyonghui0214@bjhmoh.cn
  • 基金资助:
    中央高校基本科研业务（BJ-2020-056）

Application of anti-Xa factor activity assay in low molecular weight heparin anticoagulation in hemodialysis patients 

WANG Zhen-xing1, XU Leng-nan1, FU Pei-jie1, DANG Xin1, MAO Yong-hui   

  1. 1Department of Nephrology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric medicine, Chinese Academy of Medical Sciences, Beijing 100005, China
  • Received:2021-11-08 Revised:2021-12-05 Online:2022-05-12 Published:2022-05-12
  • Supported by:
    Fees for basic scientific research in the central university of Peking Union Medical College

PDF

208

摘要： 低分子肝素（low molecular weight heparin，LMWH）是普遍应用的抗凝剂之一，临床常通过抗Xa因子活性来监测其抗凝效应以及评估出血风险，合理的抗Xa因子活性区间在临床指南也都有相应推荐。而具体到血液透析患者中，使用LMWH抗凝时抗Xa因子的监测目标范围尚未形成共识，本综述主要论述抗Xa因子活性检测在血液透析LMWH抗凝中的应用价值，以及具体监测策略的研究进展。

关键词: 血液透析, 低分子肝素, 抗Xa因子活性

Abstract: Low molecular weight heparin (LMWH) is one of the commonly used anticoagulants. Its anticoagulation effect and bleeding risk are often monitored by the anti-Xa factor activity. Appropriate anti-Xa factor activity range is also recommended in clinical guidelines. As for hemodialysis patients using LMWH, there is no consensus about the target range of anti-Xa factor activity. This review mainly discusses the value of anti-Xa factor activity assay in LMWH anticoagulation for hemodialysis and the recent progresses in its specific monitoring strategies.

Key words: Hemodialysis, Low molecular weight heparin, Anti-Xa activity

中图分类号: